Platelet-to-lymphocyte ratio is an independent predictor of chemoradiotherapy-related esophageal fistula in esophageal cancer patients

Dong Han,Jiajia Zhang,Jingjing Zhao,Tongda Lei,Xi Chen,Tian Zhang,Hui Wei,Yong Guan,Jing Wang,Wencheng Zhang,Lujun Zhao,Jun Wang,Zhiyong Yuan,Yongchun Song,Ningbo Liu,Qingsong Pang,Ping Wang

DOI: https://doi.org/10.21037/atm-20-4053

IF: 3.616

2020-09-01

Annals of Translational Medicine

Abstract:BACKGROUND: Neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and monocyte-to-lymphocyte ratio (MLR) are all markers of systemic inflammation response. The role of systemic inflammation in the development of esophageal fistula (EF) has yet to be defined. This study aimed to investigate the predictive value of hematologic measures of inflammation and to set up a predictive model.METHODS: The data of esophageal cancer (EC) patients who received chemoradiotherapy (CRT) in our institution between January, 2015 and January, 2018 were retrospectively collected. The NLR, PLR, and MLR of these enrolled patients were calculated. Univariate and multivariate analyses were performed to find the independent risk factors of EF. Moreover, a nomogram model was developed to predict the probability of fistula occurring in EC patients.RESULTS: For PLR, the optimal cut-off value was 153. Patients with PLR >153 had a higher probability of developing fistula than those with PLR ≤153 (P<0.001). Multivariate analyses revealed that esophageal stenosis, ulcerative tumor, and PLR were independent factors for EF. Subsequently, a novel nomogram was set up with the C-index of 0.77 to predict the risk of developing EF in EC patients who received CRT.CONCLUSIONS: PLR is an independent predictive indicator for EC patients who receive CRT. These findings will help to facilitate individual risk stratification for the development of EF in patients with EC.

oncology,medicine, research & experimental

What problem does this paper attempt to address?

### Problems the Paper Attempts to Solve

This paper aims to explore the value of the platelet-lymphocyte ratio (PLR) as a predictive indicator for the risk of esophageal fistula in patients with esophageal cancer after receiving chemoradiotherapy and to establish a predictive model.

#### Specific Research Content:
1. **Background**: The incidence of esophageal cancer is very high in China, with squamous cell carcinoma accounting for the vast majority. Although immune checkpoint inhibitors have shown promise in the treatment of esophageal cancer, chemoradiotherapy remains the standard treatment for unresectable esophageal cancer. However, chemoradiotherapy can lead to various side effects, among which esophageal fistula is one of the most severe complications.

2. **Research Objective**: To investigate the relationship between systemic inflammatory response markers (such as neutrophil-lymphocyte ratio [NLR], platelet-lymphocyte ratio [PLR], and monocyte-lymphocyte ratio [MLR]) and the occurrence of esophageal fistula, and to establish a predictive model to assess the risk of esophageal fistula after chemoradiotherapy.

3. **Main Findings**: The study found that PLR is an independent predictive indicator that can be used to predict the risk of esophageal fistula in patients with esophageal cancer after receiving chemoradiotherapy. The optimal cutoff value for PLR is 153, and patients with values above this threshold have a higher risk of developing a fistula.

4. **Conclusion**: PLR is an independent predictive indicator that helps in individualized risk stratification, thereby assisting clinicians in better managing the chemoradiotherapy-related risks in patients with esophageal cancer.